Inhibrx Biosciences, Inc. INBX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Inhibrx Biosciences, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s debt-to-equity?
- Inhibrx Biosciences, Inc. (INBX) reported debt-to-equity of 13.4× in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s debt-to-equity changed year-over-year?
- Inhibrx Biosciences, Inc.'s debt-to-equity increased by 22139.5% year-over-year, from 0.1× to 13.4×.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s debt-to-equity?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s debt-to-equity has grown at a 66.5% compound annual growth rate (CAGR), from 4.8× to 13.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.